肺動脈高血壓市場規模、佔有率和成長分析：按藥物類別、類型、給藥途徑、分銷管道和地區分類 - 2025-2032 年行業預測

2023年全球肺動脈高血壓市場規模將為77.9億美元，從2024年的82億美元成長到2032年的124億美元，預計在預測期內（2025-2032年）複合年成長率為5.3%。

由於幾個關鍵因素，包括盛行率的增加、政府對孤兒藥開發的支持增加以及老年人口的增加，肺動脈高血壓（PAH）市場預計將成長。根據系統性評價，PAH的盛行率為每10萬人0.4%至1.4%，全球30歲至79歲的人口估計有12.8億人患有高血壓，主要是低血壓患者－受影響於中等收入國家。世界衛生組織設定了一個重要目標，從2010年到2030年將高血壓盛行率降低33%，強調需要在這一領域進行進一步的研究和治療方法。總而言之，這些發現為 PAH 治療的進步帶來了希望。

目錄

介紹

• 研究目的
• 調查範圍
• 定義

調查方法

• 資訊採購
• 二手資料和主要資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 按細分市場的機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制因素和挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 價格分析

肺動脈高血壓市場規模：依藥物類別

• 市場概況
• 內皮素受體拮抗劑（ERA）
• PDE-5抑制劑
• 前列腺環素和前列腺環素類似物
• SGC刺激器

肺動脈高血壓市場規模：依類型

• 市場概況
• 品牌
• 非專利的

肺動脈高血壓市場規模：依給藥途徑分類

• 市場概況
• 口服
• 靜脈/皮下
• 吸入

肺動脈高血壓市場規模：依通路分類

• 市場概況
• 醫院
• 零售藥房
• 網路藥房

肺動脈高血壓市場規模

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東/非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東/非洲

競爭資訊

• 前5名企業對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024年）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分類的佔有率分析
  • 收益與前一年同期比較（2022-2024）

主要企業簡介

• United Therapeutics Corporation（United States）
• Bayer AG（Germany）
• GlaxoSmithKline plc（United Kingdom）
• Gilead Sciences, Inc.（United States）
• Novartis International AG（Switzerland）
• Pfizer Inc.（United States）
• Merck & Co., Inc.（United States）
• Bristol-Myers Squibb Company（United States）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Viatris Inc.（United States）
• Sun Pharmaceutical Industries Ltd.（India）
• Alembic Pharmaceuticals Ltd.（India）
• Aerami Therapeutics Holdings Inc.（United States）
• Asklepion Pharmaceuticals LLC（United States）
• Keros Therapeutics（United States）
• Liquidia Corporation（United States）
• Ferrer（Spain）
• Gossamer Bio（United States）

結論和建議

Global Pulmonary Arterial Hypertension Market size was valued at USD 7.79 billion in 2023 and is poised to grow from USD 8.2 billion in 2024 to USD 12.4 billion by 2032, growing at a CAGR of 5.3% during the forecast period (2025-2032).

The pulmonary arterial hypertension (PAH) market is poised for growth due to several key factors, including the increasing incidence of the disease, enhanced government support for orphan drug development, and a growing elderly population. A systematic review highlighted the prevalence of PAH, indicating it affects between 0.4% and 1.4% of individuals per 100,000, with an estimated 1.28 billion people aged 30-79 globally affected by hypertension, predominantly in low- and middle-income countries. The WHO has set significant targets to reduce hypertension prevalence by 33% from 2010 to 2030, emphasizing the need for further research and treatment options in this area. Collectively, these insights set a promising stage for advancements in the PAH treatment landscape.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Pulmonary Arterial Hypertension market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Pulmonary Arterial Hypertension Market Segmental Analysis

Global Pulmonary Arterial Hypertension Market is segmented by Drug Class, Type, Route of Administration, Distribution Channel and region. Based on Drug Class, the market is segmented into Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs and SGC Stimulators. Based on Type, the market is segmented into Branded and Generics. Based on Route of Administration, the market is segmented into Oral, Intravenous/ subcutaneous and Inhalational. Based on Distribution Channel, the market is segmented into Hospitals, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Pulmonary Arterial Hypertension Market

The global pulmonary arterial hypertension (PAH) market is experiencing significant growth due to the increasing prevalence of this rare yet progressive condition, which is characterized by elevated blood pressure in the arteries leading to the lungs. Factors contributing to this rise include aging populations, a growing incidence of risk factors such as obesity, and advancements in diagnostic techniques. Consequently, there is a heightened demand for effective PAH treatments. Furthermore, the development of innovative therapies, including prostacyclin analogues, endothelin receptor antagonists, and phosphodiesterase inhibitors, has bolstered market growth due to their improved efficacy and safety profiles, ultimately driving greater patient interest and need for these medications.

Restraints in the Global Pulmonary Arterial Hypertension Market

The global market for pulmonary arterial hypertension (PAH) faces certain constraints due to the limited pool of patients affected by this rare disease. Unlike more prevalent chronic conditions, PAH has a low incidence rate, which can significantly impact the commercial potential of therapeutic drugs designed for treatment and may deter investment in research and development. Additionally, diagnosing PAH requires a series of complex tests, including echocardiography, right heart catheterization, and pulmonary function assessments. Furthermore, symptoms such as fatigue and shortness of breath are often vague and can be misattributed to other health issues, resulting in delayed or incorrect diagnoses that hinder patient access to appropriate care.

Market Trends of the Global Pulmonary Arterial Hypertension Market

The Global Pulmonary Arterial Hypertension (PAH) market is witnessing a significant shift towards personalized medicine, driven by technological advancements and a deeper comprehension of the disease's genetic underpinnings. Pharmaceutical companies are heavily investing in research and development initiatives aimed at discovering biomarkers that can enhance the predictability of disease progression and treatment efficacy. This trend is fostering the creation of tailored therapies that specifically address varying genetic mutations associated with PAH, thereby improving patient outcomes. As a result, the market is poised for robust growth, characterized by innovation, a focus on individualized treatment regimens, and a commitment to precision healthcare solutions.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Pulmonary Arterial Hypertension Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• Endothelin Receptor Antagonists (ERAs)
• PDE-5 Inhibitors
• Prostacyclin and Prostacyclin Analogs
• SGC Stimulators

Global Pulmonary Arterial Hypertension Market Size by Type & CAGR (2025-2032)

• Market Overview
• Branded
• Generics

Global Pulmonary Arterial Hypertension Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Intravenous/ subcutaneous
• Inhalational

Global Pulmonary Arterial Hypertension Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospitals
• Retail Pharmacies
• Online Pharmacies

Global Pulmonary Arterial Hypertension Market Size & CAGR (2025-2032)

• North America (Drug Class, Type, Route of Administration, Distribution Channel)
  • US
  • Canada
• Europe (Drug Class, Type, Route of Administration, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Type, Route of Administration, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Type, Route of Administration, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Type, Route of Administration, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• United Therapeutics Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis International AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alembic Pharmaceuticals Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aerami Therapeutics Holdings Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Asklepion Pharmaceuticals LLC (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Keros Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Liquidia Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ferrer (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gossamer Bio (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations